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Abstract
Ras association domain family protein 1A (RASSF1A) is a tumor suppressor gene silenced in cancer. Here we report that
RASSF1A is a novel regulator of intestinal inflammation as Rassf1a+/2, Rassf1a2/2 and an intestinal epithelial cell specific
knockout mouse (Rassf1a IEC-KO) rapidly became sick following dextran sulphate sodium (DSS) administration, a chemical
inducer of colitis. Rassf1a knockout mice displayed clinical symptoms of inflammatory bowel disease including: increased
intestinal permeability, enhanced cytokine/chemokine production, elevated nuclear factor of kappa light polypeptide gene
enhancer in B-cells (NFkB) activity, elevated colonic cell death and epithelial cell injury. Furthermore, epithelial restitution/
repair was inhibited in DSS-treated Rassf1a2/2 mice with reduction of several makers of proliferation including Yes
associated protein (YAP)-driven proliferation. Surprisingly, tyrosine phosphorylation of YAP was detected which coincided
with increased nuclear p73 association, Bax-driven epithelial cell death and p53 accumulation resulting in enhanced
apoptosis and poor survival of DSS-treated Rassf1a knockout mice. We can inhibit these events and promote the survival of
DSS-treated Rassf1a knockout mice with intraperitoneal injection of the c-Abl and c-Abl related protein tyrosine kinase
inhibitor, imatinib/gleevec. However, p53 accumulation was not inhibited by imatinib/gleevec in the Rassf1a2/2
background which revealed the importance of p53-dependent cell death during intestinal inflammation. These
observations suggest that tyrosine phosphorylation of YAP (to drive p73 association and up-regulation of pro-apoptotic
genes such as Bax) and accumulation of p53 are consequences of inflammation-induced injury in DSS-treated Rassf1a2/2
mice. Mechanistically, we can detect robust associations of RASSF1A with membrane proximal Toll-like receptor (TLR)
components to suggest that RASSF1A may function to interfere and restrict TLR-driven activation of NFkB. Failure to restrict
NFkB resulted in the inflammation-induced DNA damage driven tyrosine phosphorylation of YAP, subsequent p53
accumulation and loss of intestinal epithelial homeostasis.
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Introduction
The Ras association domain family protein 1A (RASSF1A) is
frequently lost in human cancers by promoter-specific methylation
[1]. RASSF1A (but not RASSF5A/Nore1A) was previously shown
to associate with tumor necrosis factor a receptor 1 (TNF-R1) to
promote cell death [2]. Although RASSF5A lacks association with
TNF-R1, Rassf5a2/2 mice do have defective TNFa responses
suggesting that RASSF5A may influence TNFa signaling and
apoptosis through alternate pathways such as interactions with
sterile-20 like pro-apoptotic kinases, MST1/2 (mammalian Hippo)
[3]. Rassf1a2/2 mice are viable and fertile, have normal cell cycle
parameters and sensitivity to DNA-damaging agents and show no
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signs of gross genomic instability [4,5]. They do, however, develop
tumors in response to chemical carcinogens and develop
spontaneous tumors by 18 months of age. Several animals had
B-cell lymphomas and others had tumors localized within the
gastrointestinal tract suggesting an important role for RASSF1A in
gastrointestinal physiology [4,5]. Recently, it was demonstrated
that the p532/2/Rassf1a2/2 double knockout mice are viable,
fertile and developmentally normal [6]. However, the loss of p53
(even in the heterozyogous state) led to .60% of the animals
developing tumors in the absence of Rassf1a [6]. These tumors
include several adenocarcinomas and sarcomas localized within
the lungs. However, there was no evidence of colonic hyperplasia
[6]. The p532/2/Rassf1a2/2 double knockout mice also revealed
enhanced cytokinesis failure and chromosomal abnormalities
leading to aneuploidy which suggests importance in mitotic
regulation and tumor suppressor function.
It has been determined that 80% of sporadic colorectal cancer
(CRC) tumors have somatic and germline mutations within the
tumor suppressor gene, adenomatous polyposis coli (APC) [7]. In
the absence of APC, b-catenin freely translocates to the nucleus
where it signals an intracellular cascade resulting in the
transcription of hundreds of genes [8–10]. The loss of RASSF1A
in the context of the APCmin/+ mice (Rassf1a2/2APCmin/+ mice) has
been reported to result in increased b-catenin nuclear localization,
intestinal adenomas and poorer survival than single knockout
littermate controls [11]. These data would suggest the importance
of the early loss of RASSF1A during premalignant formation of
adenocarcinomas that may lead to increased malignant transfor-
mation and tumorigenesis. The loss of both APC and RASSF1A
function may be key initiating events in the formation of CRC and
these observations highlight the importance of RASSF1A in
intestinal physiology [10,12].
It has been demonstrated that TNF-R1 is a unique death
receptor that can activate a cell death pathway through
RASSF1A, triggering Bax activation and mitochondrial-driven
apoptosis [1,2,13,14]. In addition, TNF-R1 can also promote a
pro-inflammatory response through nuclear factor kappa B
(NFkB) pathways [15]. NFkB is an important mediator of
inflammation and the pathogenesis of intestinal inflammation
and inflammatory bowel disease (IBD) [16]. TLRs can also
activate a potent NFkB response and defend against invading
pathogens [17]. Of the RASSF family members, RASSF6 and 8
were demonstrated to modulate NFkB activity but a mechanism
was not proposed [18,19]. Recently, Song et al. (2012) demon-
strated that RASSF2 can associate with the IKK complex to
inhibit NFkB [20] and several reports indicate that RASSF1C and
8 may influence the function of the Wnt/b-catenin pathways,
pathways important for the appearance of intestinal tumorigenesis
[19,21].
It is currently unknown if RASSF1A can influence NFkB
activation via TNF-R1 or TLR pathways. However, epigenetic
analysis does reveal promoter specific methylation of RASSF1A
resulting in loss of expression in ulcerative colitis (UC) patients
[22], a form of IBD. Interestingly, IL-6 can drive epigenetic loss of
RASSF1A via DNA methyltransferase 1 (DNMT1) up-regulation
[23,24] suggesting that inflammation can drive expression loss of
RASSF1A. In this study, we demonstrate an in vivo function for
RASSF1A in restricting NFkB-dependent inflammation linked to
the TLR pathway. Furthermore, we can demonstrate that NFkB-
dependent inflammation can modulate epithelial proliferation
and the appearance of tyrosine phosphorylation of the Hippo
pathway target, Yes-associated protein (YAP). We believe that ty-
rosine phosphorylated YAP can up-regulate pro-apoptotic genes to
drive intestinal epithelial apoptosis. Restricting NFkB-dependent
inflammation and tyrosine phosphorylation of YAP will maintain
epithelial homeostasis, promote epithelial restitution and allow
recovery from inflammation induced injury.
Experimental Procedures
All animal experiments/husbandry have been approved and
follow the guidelines of the Canadian Animal Care and Use
Committee and the animal ethics board at the University of
Alberta (permit numbers #461 and 639). All animals (except for
the Rassf1a IEC-KO and Rassf1a IEC-WT) were on the C57BL/6
background. Rassf1a IEC-KO and Rassf1a IEC-WT were on the
C57BL/6-129 background. Although the loss of Rassf1a can lead
to tumor formation, the loss of Rassf5a (Rassf5a2/2 mice) has not
been documented to display an overt phenotype nor tumor
formation as they age. We therefore used the Rassf5a2/2 mice as a
related control [3]. Villin-Cre transgenic mice [B6.SJL-Tg(Vil
cre)997Gum/J] was obtained from Jackson Laboratories.
Genotyping of intestinal specific knockout mice
PCR was utilized to detect the conditional allele of Rassf1a
(RSF-C/RSF-3), for the deletion of exon 1a of RASSF1A (RSF-5/
RSF-3) [5] and the presence of the Villin Cre-transgene
(IMR1878/IMR1879/IMR0015 and IMR0016) (Jackson Labo-
ratories) as described previously. RSF-3 (reverse primer), 59-CCA
GGC TTC CTT CTC ACT CCT CTG CCG C-39; RSF-C
(forward primer), 59-CTC GCC CCT GTC AAA GAA AGC
TGC TCT GGG GTT CT-39; RSF-5 (forward primer), 59-CTC
GCC CCT GTC AGA CCT CAA TTT CCC-39, IMR1878 (Cre
Transgene), 59-GTG TGG GAC AGA GAA CAA ACC-39;
IMR1879 (Cre Transgene), 59-ACA TCT TCA GGT TCT GCG
GG-39; IMR0015 (internal positive control forward), 59-CAA
ATG TTG CTT GTC TGG TG-39; IMR0016 (internal positive
control reverse), 59-GTC AGT CGA GTG CAC AGT TT-39.
PCR cycle conditional allele or deleted gene: 94uC for 3 min (1
cycle) followed by 94uC for 30 s, 65uC for 1 min, 72uC for 30 s (30
cycles) with a final cycle of 72uC for 10 min and keep at 4uC till
the end. PCR for Cre Transgene, 1 cycle at 94uC for 3 min
followed by 35 cycles of 94uC for 30 s, 62uC for 1 min, 72uC for
1.5 min, with a final step of 72uC for 1 min and keep at 4uC till
the end. RSF-C/RSF-3 produces a 400 bp fragment for wild-type
allele of Rassf1a and a 480 bp fragment for conditioned allele.
RSF-5/RSF-3 produces a 400 bp fragment only in the mouse
tissue that has Exon 1a of Rassf1a deleted. The Cre Transgene
genotyping produces a 200 bp fragment for the wild-type allele
and an 1100 bp fragment for the Cre Transgene.
Mouse histology
The descending colon was isolated, fixed in z-Fix (Anatech Ltd)
and paraffin-embedded. All inflammation scores were obtained
utilizing blinded scoring by a gastrointestinal pathologist (Dr.
Aducio Thiesen) based on infiltration of enterocytes, neutrophils,
lamina propria cellularity, crypt structure and epithelial hyperpla-
sia (scored as 0 – 2 where 2 = maximal injury).[25] Crypt depth
was measured using a Leica SP5 confocal microscope at 40X
magnification. Immunohistochemistry (IHC) and hematoxylin and
eosin (H&E) staining were carried out using standard techniques.
Isolation of mouse cells
Splenoctyes were obtained by excising the spleen and crushing it
between two frosted glass slides to generate a single cell suspension.
Red cell lysis (8.3 g/L NH4Cl, 0.01 M Tris-HCL pH 7.5) was
utilized to remove the erythrocytes and the remaining spleen cells
(mainly B, T cells and monocytes) were cultured ex vivo in RPMI/
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10% Bovine growth serum/1% Penicillin-Streptomycin. Bone
marrow derived macrophages (BMDM) were isolated from the femur
and grown in DMEM/10% Bovine growth serum/1% Penicillin-
Streptomycin for 2–3 days on tissue culture dishes [26]. Non-
adherent cells (mainly macrophages) were transferred to Petri
dishes and grown in DMEM/10% Bovine growth serum/1%
Penicillin-Streptomycin containing 20% L cell conditioned media
(supernatant from L cells). Macrophages are the only cells that will
adhere to the Petri dish. Purity was determined by flow-cytometry
analysis using F4/80 and CD4+ markers. Intestinal crypt cells were
isolated as outlined previously [27]. Briefly, colons were flushed
with cold 16PBS, cut open longitudinally and then soaked in 1X
PBS with gentle shaking for 20 minutes. The colons were cut into
small pieces and incubated with 0.04% sodium hypochlorite for
30 min with gently shaking in a 10 cm2 Petri dish. Following
incubation, the colon pieces were removed and allowed to shake
continuously at room temperature for 30 minutes in a solution
containing 1X PBS/1 mM EGTA/1 mM EDTA. Cells were then
dislodged by pipetting the tissue up and down using a 25 mL
serological pipette until the solution became cloudy. The
supernatant was removed (containing the crypt cells) and
centrifuged at 3000 rpm for 10 minute to collect the crypt cells.
The cells were washed in 1X PBS, transferred to an eppendorf
tube, pulse spun to pellet the cells followed by nuclear extraction as
previously described [26]. Generally, one crypt cell preparation for
nuclear extraction was obtained from two colons. Colon protein
lysates were prepared by homogenizing in TPER lysis buffer
(Fisher Scientific) following isolation.
Mouse colonoscopy
Colonoscopy was carried out using a human ureteroscope from
Olympus URF [Uretero-Reno Fiberscope] Type P5 within the
Center for Excellence in Gastrointestinal Inflammation and
Immunity Research (CEGIIR) group at the University of Alberta
under isoflurane anesthesia.
Innate immunity analysis
Animals were administered 3% w/v DSS (#160110, molecular
weight of 10000, MP Biomedicals) in the drinking water for 7 days
followed by recovery for 7 days. They were monitored for:
piloerection, bloatednesss, tremors, lack of movement, rectal
bleeding and weight loss (all on a scale of 0–5 with 5 being very
severe, adapted from Madsen et al.) [25]. Animals were
euthanized once rectal bleeding became grossly apparent. For
weight loss, a score of 0 for no weight loss, 1 if ,5% loss, 2 for 5–
10% loss, 3 for 10 – 15% loss, 4 for 15 – 20% loss and a score of
5.20% loss in initial body weight. Disease activity indices (DAI)
were the sum of all individual scores. All animals were 10 – 12
weeks of age or .25 g in body weight at the beginning of the
experiment.
Gut permeability experiments
Following innate immunity activation, animals were starved
overnight, FITC-Dextran (0.6 mg/g body weight) was orally
administered and 4 hours later blood was collected by cardiac
puncture. The resulting serum obtained was analyzed for
fluorescein isothiocynate (FITC)-Dextran by fluorimetry (excita-
tion 492 nm; emission, 525 nm; PerkinElmer flurometer). In
addition, liver, spleen and mesenteric lymph nodes were removed,
homogenized in 1X PBS and 10 mL of the lysate were cultured on
MacConkey agar plates to detect Gram-negative bacteria trans-
located from the gut. Similarly, 10 mL of blood was cultured on
MacConkey agar plates.
In vitro kinase assays
MST1: MST1 was immunoprecipitated overnight from 600 mg
of TPER homogenized colon lysate (rabbit anti-MST antibody,
Cell Signaling#3682) was used as described previously [28].
Protein A sepharose beads were used to immobilize the MST1
kinase complex for 1 hour, washed twice with wash buffer and
twice with kinase buffer (40 mM HEPES, pH 7.5/20 mM
MgCl2/20 mM b-glycerophosphate/0.1 mM sodium vanadate).
The kinase reaction contained 25 mM ATP/5 mCi 32-P-c-ATP
and 2 mg of histone H2B in 20 mL of kinase buffer. It was carried
out for 20 minutes at 30uC, samples were separated by SDS-
PAGE, dried down using a gel dryer and autoradiographed.
Coomassie blue panel reveals the amount of Histone H2B used in
the assay.
c-ABL: ABL was immunoprecipitated overnight from 600 mg of
TPER homogenized colon lysate using 1 mg each of anti-c-ABL
antibody from BD Bioscience (#554148) and Santa Cruz (sc-121).
Protein A sepharose beads were used to immobilize the c-ABL
kinase complex for 1 hour, washed twice with wash buffer (50 mM
Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM sodium
vanadate, 1 mM EDTA) and twice with kinase buffer (30 mM
HEPES, pH 7.1/10 mM MgCl2/2 mM MnCl2/5 mM DTT/
10% glycerol/0.2 mM sodium vanadate). The kinase reaction
contained 10% glycerol/1 mM ATP/5 mCi 32-P-c-ATP and 6 mg
of lysate from HCT116 cells transiently transfected with FLAG-
YAP in 30 mL of kinase buffer. The reaction was carried out for 30
minutes at 30uC, samples were separated by SDS-PAGE, dried
down using a gel dryer and autoradiographed. Coomassie blue
staining confirmed expression levels of FLAG-YAP (Fig. S7D).
NFkB electromobility shift assay (EMSA)
This was carried out as previously described [26]. Briefly,
duplex DNA specific for the NFkB binding site was end-labeled
with [c-32P] ATP by using T4 polynucleotide kinase, purified
using a G-50 sephadex column (Roche) and allowed to associate
with 4 mg of the nuclear extracts containing NFkB for 30 min at
room temperature. The oligonucleotide was AAATGTGG-
GATTTTCCCATGA for crypt cell NFkB analysis (the NFkB
binding site from the IL-6 promoter) and TCAGAGGG-
GACTTTCCGAGAGG for BMDM NFkB analysis (the NFkB
binding site from the IL-8 promoter). DNA/protein complexes
were then separated by non-denaturing gel electrophoresis, dried
onto Whatman filter paper and autoradiographed. Nuclear
extracts were prepared using NE-PER (ThermoFisher Scientific)
as per manufacturer’s instructions). Binding buffer was 100 mM
Tris-HCL pH 6.5, 500 mM KCl, 1.2 mM EDTA, 12 mM DTT,
20% glycerol and 1 mg Salmon Sperm DNA. The purity of
fractions was confirmed with anti-b-tubulin (cytosolic fraction) or
anti-lamin B (nuclear fraction) (data not shown).
Determination of reactive oxygen species (ROS)
To determine the degree of ROS generated, a fluorometric
assay, utilizing the unique intracellular oxidation of 29,79-
dichlorofluorescin diacetate (DCF-DA), was used. Freshly isolated
crypt cells were seeded into 96-well plates in triplicate. Cells were
immediately treated with 5 mM DCF-DA and fluorescence was
monitored over 45 minutes in the dark. Fluorescence was
measured using a Synergy H4 Microplate Reader (Biotek
Instruments) set to 37uC. Measurements were made using a
485/20 nm excitation and a 528/20 nm emission filter pair and a
gain sensitivity setting of 55%. Readings were made from the
bottom every 30 seconds for a total of 45 minutes.
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Statistics
Statistical analyses were performed using one-way ANOVA and
Students t-test (two-tailed), as indicated using the GraphPad Prism
5 software. All experiments were carried out at least three times.
Error bars in all graphs represent the standard error. Statistics for
individual experiments are indicated with the graph or figure
legends.
Results
Decreased survival of Rassf1a2/2 mice following
exposure to DSS
Maintaining intestinal homeostasis relies on the ability to
control insults from resident microbes in the intestinal lumen by
maintaining and preserving intestinal permeability function. DSS
is a chemical irritant of the colonic mucosa resulting in epithelial
barrier damage, microbial invasion and activation of TLR-
expressing epithelial cells triggering NFkB activation. Administra-
tion of DSS in the drinking water results in colitis in rodents,
mimicking human symptoms of UC. These symptoms include
weight loss, diarrhea and rectal bleeding. Upon DSS treatment,
Rassf1a2/2 mice became sick within 6 – 9 days post-treatment
(Fig. 1A) with reduced activity, piloerection, a general moribund
state/hunched posture, lack of grooming, severe rectal bleeding
and significantly reduced survival. Wild-type and Rassf5a2/2 mice
displayed only mild symptoms of DSS-induced intestinal injury
and demonstrated full recovery from DSS exposure (Fig. 1A).
Rassf1a2/2 mice revealed .25% loss of body weight (Fig. 1B),
increased DAI (Fig. 1C), significantly shortened colon (Fig. 1D)
and decreased crypt depth (Fig. S1A) in contrast to wild-type and
Rassf5a2/2 mice. Histological sections stained with H&E revealed
severe colonic disruption with mucosal/crypt damage (cryptitis
and crypt abscesses) in Rassf1a2/2 mice with evident cellular
infiltrates composed of immune cells (Fig. 1E and Fig. S1B). DSS-
treated wild type and Rassf5a2/2 mice revealed minimal colonic
morphology changes and significantly less cellular infiltrates
(Fig. 1C). Surprisingly, the Rassf1a+/2 mice also demonstrated
similar symptoms to the Rassf1a2/2 mice suggesting haploinsuffi-
ciency at the Rassf1a locus (Fig. 1A). Since DSS-treated Rassf1a+/2
mice phenocopy the Rassf1a2/2 mice data henceforth is presented
for the Rassf1a2/2 mice for most of this article. Genotyping and
western blot confirmation of loss of Rassf1a is shown in Fig. S1C.
DSS-treated Rassf1a2/2 mice have enhanced
inflammation
Histological sections from DSS-treated Rassf1a2/2 colons also
revealed mild epithelial hyperplasia as reflected by increased
inflammation scores in Rassf1a2/2 treated mice (Fig. 2A). Using
mouse colonoscopy, we observed significant DSS-induced injury
by day 8 in Rassf1a2/2 versus wild-type or Rassf5a2/2 mice.
Reduction of proper colonic striations and disappearance of a
normal vascular pattern together with the presence of erythema
was observed in the Rassf1a2/2 mice indicating active inflamma-
tion (Fig. 2B). Together, these findings suggest that RASSF1A is
important for protection against DSS-induced intestinal inflam-
mation.
To determine the mechanism of DSS-induced injury in
Rassf1a2/2 mice, levels of inflammatory biomarkers were assessed.
Serum levels of IL-6, IL-12 and MCP-1 (but not IL-1b, TNFa,
IFNc or IL-23) were elevated in Rassf1a2/2 mice compared to
wild-type or Rassf5a2/2 mice (Fig. 2C – E). Following DSS
treatment, NFkB specific activity in bone marrow cells from
Rassf1a2/2 animals was significantly higher than in wild-type or
Rassf5a2/2 bone marrow cells (Fig. 2F). The detected activity was
specific for NFkB (Fig. 2F, lane 4) and lost in the presence of a cold
competitor oligonucleotide or an NFkB mutant DNA binding
oligonucleotide (Fig. 2F, lanes 4 and 5, respectively). We further
characterized inflammation injury in Rassf1a2/2 versus wild-type
mice by measuring myeloperoxidase (MPO, a glycoprotein rapidly
released by activated neutrophils) and hyaluronic acid (HA)
release. Following DSS-induced intestinal injury, HA synthase
(HAS) upregulates HA production in macrophages and lamina
propria lymphocytes [29], targeting TLR2 and TLR4, and
subsequently promoting TLR4/2-driven NFkB activity [30]. We
observed a significant increase in both serum and colon tissue
levels of MPO (Fig. S1D) and serum HA levels (Fig. S1E) in DSS-
treated Rassf1a2/2 mice (a 2 – 3 fold increase in both markers was
observed). Elevated HA levels may indicate a sustained need to
activate TLR4-driven protective responses to promote epithelial
repair in the continued presence of inflammation-induced damage
[30]. In contrast, elevation of MPO may be detrimental to the
recovery from DSS-induced injury and may have significantly
contributed to the decreased survival of Rassf1a2/2 mice.
Ex vivo analysis of Rassf1a2/2 stimulated bone marrow
cells reveal abnormal NFkB regulation
Our in vivo results implicate NFkB in intestinal inflammation in
DSS-treated Rassf1a2/2 mice. Activation of intestinal epithelial
cells (IECs) generally results in signals transmitted to the bone
marrow and lymph nodes, resulting in activation of macrophages
and lymphocytes (that is, the adaptive immune response). The
reported changes in NFkB DNA-binding activity in bone marrow
cells (Fig. 2F) suggested that DSS-driven activation of IECs can be
transmitted to the bone marrow to promote an adaptive immune
response and amplify NFkB activity. Alternatively, the intrinsic
loss of RASSF1A in hematopoietic cells could also cause
hyperactivation of NFkB in the immune cells and reflect an
important role for RASSF1A in these cells. This issue was
addressed by culturing bone marrow derived macrophages
(BMDM), splenocytes or crypt cells ex vivo (from untreated animals)
and stimulating them with lipopolysaccharide (LPS) or DSS (both
activators of TLR4) [29,30]. Normally, NFkB is inhibited by
IkBawhich is phosphorylated and targeted for degradation
following LPS or DSS stimulation, allowing nuclear translocation
and activation of NFkB. Analysis in Rassf1a2/2 BMDM revealed a
sustained increase in IkBa phosphorylation following LPS
stimulation (even up to 2 hours post LPS-addition [data not
shown]); while both wild-type and Rassf5a2/2 BMDM showed
transient expression of IkBa phosphorylation (Fig. 3A). This
indicated that there was an inherent failure of BMDM from
Rassf1a2/2 mice to downmodulate NFkB activity when compared
to LPS or DSS-treated BMDM from wild type or Rassf5a2/2
mice.
Not surprisingly, ex vivo LPS-stimulated Rassf1a2/2 BMDM
revealed elevated production of NFkB-regulated pro-inflammato-
ry elements (IL-6 and MCP-1) (Fig. 3B – C) as well as IL-12 and
TNFa (Fig. S2A – B). Both IL-6 and IL-12 were also secreted from
Rassf1a2/2 BMDM upon treatment with 3% DSS (Fig. 3D – E).
IL-10 (an anti-inflammatory cytokine) and MCP-1 were un-
changed upon DSS stimulation (Fig. S2C and data not shown,
respectively) nor was IL-10 changed with LPS stimulation (data
not shown). The elevated production of IL-6 and IL-12 (upon LPS
or DSS stimulation) and MCP-1 (upon LPS stimulation) can be
inhibited by utilizing the NFkB inhibitor, (E)-2-Fluoro-49-methox-
ystilbene (methoxyresveratrol, IC50 = 150 nM) (Fig. 3B – E and
Fig. S2A). Methoxyresveratrol has been demonstrated to effec-
tively inhibit LPS-induced COX-2 mRNA production as well as
TNFa-driven NFkB activation in cultured cells [31]. These data
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Figure 1. Rassf1a2/2 animals are sensitive to dextran sodium sulphate (DSS) treatment.Mice were subjected to 3% DSS solution followed by day 7
replacement with regular water to allow for recovery. (A) A Kaplan-Meier curve monitoring% survival following DSS treatment. P value,0.0001 (WT/Rassf5a2/
2 vs Rassf1a2/2) and 0.0023 (WT/Rassf5a2/2 vs Rassf1a+/2); n=12–20. (B) Body weight changes following DSS treatment. P value =0.003 (WT/ Rassf5a2/2 vs
Rassf1a2/2); n=12 – 20. Rassf1a+/2 animals revealed between 20–25% body weight loss (data not shown). (C) Disease activity index (DAI) following DSS
treatment. P value =0.007 (WT/ Rassf5a2/2 vs Rassf1a2/2), n=12–20. Rassf1a+/2 animals revealed DAI between 9–12 (data not shown). (D) Colon length at day
9 of DSS treatment. The indicated p-values represent the difference between 2/+DSS treatments within the genotypes; p-value [WT vs Rassf1a2/2 (+DSS)]
=0.0001; WT vs Rassf5a2/2 (+ DSS) =0.01; and Rassf1a2/2 vs Rassf5a2/2 (+DSS) =0.0003. A representative picture is shown in the bottom panel indicating
how colon length was measured. DSS-treated Rassf1a+/2 revealed a similar loss of colon length (data not shown). (E) A longitudinal cross-section of the
descending colon stained with H&E is shown for untreated and DSS-treated animals. Additional images for DSS-treated Rassf1a2/2 are in Fig. S1C as well as for
untreated Rassf1a2/2 and Rassf5a2/2 colon sections. All untreated colon sections samples were very similar to untreated colon sections from wild type mice.
doi:10.1371/journal.pone.0075483.g001
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Figure 2. Rassf1a2/2 animals have elevated inflammatory biomarkers following DSS treatment. (A) Inflammation scoring of colon
sections stained with H&E. p value of wild type (+DSS) vs 1a2/2 is 0.0008 and wild type (+DSS) vs 5a2/2 is 0.290 (n = 5 – 10). (B) Colonoscopy images
of 3% DSS-treated animals. The Rassf1a2/2 mice (+DSS) were euthanized on day 9 due to disease, whereas all others recovered from 3% DSS
treatment. Untreated Rassf1a2/2 or Rassf5a2/2 mice had images similar to wild type untreated mice. (C – E) Blood serum levels of the indicated
cytokines. The p value of DSS treated wild type vs Rassf1a2/2 = 0.0001 for IL-6 and MCP-1; 0.005 for IL-12; n=10–14 per group. DSS-treated Rassf1a+/
2 revealed as similar increases in IL-6 (Figure 8C) and IL-12 (data not shown). (F) NFkB DNA binding in nuclear extracts derived from bone marrow
cells upon DSS treatment. Cold wild type or mutant NFkB oligonucleotide was added to determine the specificity of the observed band (lanes 4 and
5, respectively). Lanes 3 and 7 are the same treatment and genotype but BMDM was obtained from different animals. For (A) and (F), all untreated
results for Rassf1a2/2 and Rassf5a2/2 were similar to wild type (untreated).
doi:10.1371/journal.pone.0075483.g002
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strongly suggested that NFkB activity is driving cytokine produc-
tion ex vivo in BMDM cells from Rassf1a2/2 mice upon LPS or
DSS stimulation. In addition, it also suggests that RASSF1A may
function to restrict NFkB activation within the TLR4 pathway.
We also observe the abnormal activation of NFkB in ex vivo
stimulated colon crypt cells from Rassf1a2/2 mice upon DSS
stimulation that can also be inhibited by methoxyresveratrol
(Fig. 3F). No changes were observed between wild-type/Rassf5a2/
2 mice versus Rassf1a2/2 mice for the levels of secreted IL-1b,
IFNc? nor IL-23 from ex vivo LPS or DSS-stimulated BMDM (data
not shown). BMDM stimulation with the TLR9 activator, CpG
DNA (but not the TLR2 ligand PAM3CSK4) resulted in the
elevated production of TNFa (Fig. S2D and data not shown
respectively) and we can also observe increased cytokine/
chemokine production in isolated Rassf1a2/2 splenocytes stimu-
lated with CpG DNA (Fig. S2D) or LPS (Fig. S2E – F). Taken
together, our ex vivo data suggests that RASSF1A may have a
universal role in modulating cytokine/chemokine production in
immune cells as well as in epithelial cells and that RASSF1A may
influence both TLR4 and TLR9 pathways linked to NFkB
activation.
RASSF1A regulates intestinal epithelial homeostasis
following DSS-induced inflammation
In order to specifically explore the role for RASSF1A in
intestinal physiology, an intestinal epithelial cell specific knockout
to RASSF1A, Rassf1aIEC-KO, was generated by mating Rassf1a-LoxP
conditional mice [5] with the Villin-Cre transgenic mouse and the
knockout allele detected by PCR (Fig. 4A). Villin is an intestinal-
related cytoskeletal protein that is associated with brush border
microvilli. RASSF1A knockout was confirmed by PCR utilizing
genomic DNA from colonic sections as previously published [5].
Similar to the Rassf1a2/2 mice, DSS-treated Rassf1aIEC-KO animals
displayed ,25% survival (Fig. 4B) with significant loss of body
weight (Fig. 4C), colon length (Fig. 4D), disrupted colonic crypts
and decreased crypt depth (Fig. 4E and Fig. S3A), severe disease
activity indices (Fig. 5A) and elevated histopathological scores
(Fig. 5B). In addition, DSS-treated Rassf1aIEC-KO animals had
elevated IL-6 and MCP-1 (Fig. 5C – D), increased NFkB DNA
binding activity in Rassf1a IEC-KO bone marrow cells and colon
crypt cells (Fig. 5E) and significant increases in colonic tissue MPO
(Fig. 5F) and colonic tissue HA levels (Fig. S3B). Taken together,
these data strengthen the protective role of RASSF1A in restricting
unwanted NFkB and following DSS-induced inflammation injury.
Not surprisingly, ex vivo analysis of LPS or DSS stimulated
BMDM or splenocytes from Rassf1aIEC-KO mice revealed a wild-
type like response to LPS or DSS (compare results in Fig. S3C – D
versus Fig. 3B – E). This is consistent with RASSF1A only being
deleted in IECs and not in immune cells in the Rassf1a IEC-KO mice.
It is thus the loss of RASSF1A within the intestinal epithelial cells
that is promoting intestinal inflammation and amplifying the
response by activating BMDM. The elevated responses and high
cytokine production possibly explains the poor survival of Rassf1a
knockout mice. RASSF1A may function to restrict NFkB
activation in both colon epithelial and immune cells in order to
modulate the inflammatory response. It should be noted that in all
Rassf1aIEC-KO animals, we detected the knockout allele in the
kidney as well (Fig. 4, right panel) since villin is also expressed in
the epithelia of renal proximal tubules [32]. However, RASSF1A
immunoblotting revealed the complete loss of RASSF1A from
IEC cells but only partial loss of RASSF1A in kidney lysates from
Rassf1aIEC-KO mice (Fig. S3E). Importantly, serum creatinine,
systolic blood pressure and renal morphology were similar in
Rassf1aIEC-KO and wild-type mice before or after exposure to DSS
(Fig. S4A – C). This excludes renal failure as the cause of the poor
survival of Rassf1aIEC-KO animals upon DSS treatment.
DSS-treated Rassf1a knockout mice have increased gut
permeability
Epithelial barrier breakdown and increased permeability of the
gut occurs during severe inflammation and IBD and are associated
with increased production of cytokines [33,34]. Fortunately, IEC
layer integrity is rapidly re-established by epithelial restitution,
wound healing and/or increased epithelial proliferation after
inflammation-induced injury in order to maintain a healthy gut.
These events prevent direct exposure of lamina propria immune
cells to the intestinal microflora and a harmful inflammatory
response [35]. Thus, the epithelial integrity of DSS-treated
Rassf1a2/2 mice was examined, assessing cell repair and intestinal
permeability. Following a 7 day treatment with DSS and a one day
recovery period with regular water, animals were administered
FITC-dextran by oral gavage. Serum levels of FITC-dextran were
significantly higher in DSS-treated Rassf1a2/2 and Rassf1aIEC-KO
mice versus wild-type/Rassf5a2/2 mice, suggesting a role for
RASSF1A in maintaining permeability during the recovery phase
of DSS-induced inflammation injury (Fig. 6A). Interestingly,
spleen, liver and mesenteric lymph node extracts from DSS-
treated Rassf1a knockout animals revealed .50% bacterial
translocation also indicating increased gut permeability (Fig. 6B).
DSS-treated Rassf1a knockout mice thus have an impaired ability
to contain commensal bacterial in the colon upon inflammation-
induced insult.
Defective epithelial restitution in Rassf1a knockout mice
following DSS-induced injury
The increased epithelial permeability and decreased survival of
DSS-treated Rassf1a2/2 mice could be explained by the damage
caused by disruption of the epithelial barrier (and damaged
paracellular space), elevated cell death (apoptosis) or defects in
epithelial cell repair and lack of crypt cell proliferation [36]. Due
to increased colonic permeability and mucosal/crypt damage in
Rassf1a2/2 and Rassf1aIEC-KO mice following DSS insult (Fig. 1D –
E and Fig. 4D – E) we speculate that RASSF1A may influence
pathways involved in epithelial restitution and/or cell repair to
regain normal epithelial architecture. Proliferating cell nuclear
antigen (PCNA) staining of tissue colon sections from Rassf1a2/2
and Rassf1aIEC-KO mice treated with DSS confirmed reduced crypt
cell proliferation versus wild-type or Rassf5a2/2 (Fig. S5A). We
also observed significant PARP cleavage (a marker of late
apoptosis) in colon lysates (Fig. 6C) and increased TUNEL-
positive staining in colonic sections (a marker of condensed nuclei
and indicative of apoptosis) (Fig. 6D) from DSS-treated Rassf1a2/2
and Rassf1aIEC-KO mice. The substantial increase in apoptosis in
DSS-treated Rassf1a2/2 and Rassf1aIEC-KO mice is likely a
significant contributing factor to the decreased survival observed
for these mice in Fig. 1A and 4B.
DSS-treated Rassf1a2/2 mice triggers tyrosine
phosphorylation of yes-associated protein (YAP)
following DSS-induced injury
RASSF1A can normally promote cell death via TNF-R1 and
the loss of RASSF1A should result in decreased cell death. We, in
fact, can detect enhanced cell death by PARP and TUNEL
analysis (Fig. 6C – D). We thus explored alternative explanations
for how the loss of RASSF1A may result in increased intestinal
apoptosis. RASSF1A is a component of the Rassf/Salvador/
Hippo pathway that can modulate cell death, organ size and
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Figure 3. Rassf1a2/2 animals show increased levels of biomarkers of inflammation. (A) Ex vivo analysis of bone marrow derived macrophages
was carried out for the presence of phospho-(p)-IkBa (A, repeated in triplicate) and serum pro-inflammatory cytokine production (B – E, n = 6–10). LPS
was for 5 hours (B – C) and 3% DSS for 16 hours in media (D – E). For (B – E) n =4. (F) Colon epithelial crypt cells were isolated, cultured and stimulated
the same day with 3% DSS for 16 h. IL-6 secreted into the supernatant was quantitated (n= 4). Stimulation of colon epithelial crypt cells from the
Rassf5a2/2mice was not carried out. Stimulation of isolated colon epithelial crypt cells with LPS produced similar results (data not shown). For (B – F) all
untreated results for Rassf1a2/2 and Rassf5a2/2 were similar to wild type (untreated). The NFkB inhibitor utilized was 10 mM methoxyresveratrol.
doi:10.1371/journal.pone.0075483.g003
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Figure 4. RASSF1A intestinal cell-specific knockout (Rassf1aIEC-KO) phenocopy Rassf1a2/2 mice following DSS-induced inflammation.
(A) PCR detection of the conditional LoxP-1A allele and knockout allele for 1A upon Cre transgene expression in Rassf1aIEC-KO animals. Left panel, As
an example, animal #3 contained the IEC-specific knockout, as the conditional allele (c1) and the Cre transgene (Cre-Tg) were observed in the ear
tissue and colon (see Methods S1 for further details). C1 = conditional allele; WT= wild-type allele. Right panel, genotyping in various mouse
tissues. (B) Reduced survival of Rassf1aIEC-KO animals exposed to 3% DSS solution. P value [Rassf1aIEC-WT vs Rassf1aIEC-KO] = 0.001, n=12. (C) Decreased
body weight change following DSS treatment. P value = 0.001 (Rassf1aIEC-WT vs Rassf1aIEC-KO), n= 12. (D) Shortened colon length following
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cellular proliferation [37–39]. It is thought that in mammalian
cells, RASSF1A can function to activate MST1/2, resulting in the
activation of LATS and downstream serine phosphorylation
events [40]. Activated LATS can lead to the inactivation (by
cytoplasmic re-localization and retention) of the Yes-associated
protein (YAP), a key diver of proliferation (known as Yorkie [Yki] in
Drosophila) linked to the TEAD family of transcription factors [41]
Removal of either Yki from intestinal stem cells in Drosophila [42] or
YAP in Yap2/2 mice [43] revealed poor survival and decreased
epithelial cell proliferation in response to DSS treatment
(characteristics similar to what we have observed). However, we
are arguing for the important role of RASSF1A in restricting
NFkB and downstream effects that hyperactivation of NFkB can
cause. Although inflammation was not investigated in either of
these studies, it does suggest an important role for both RASSF1A
and YAP in modulating crypt cell proliferation and survival
following DSS-induced inflammation injury.
In the absence of RASSF1A, there was a significant reduction in
S127 phosphorylation of YAP (Fig. 6E, top panel) and enhanced
nuclear presence of p73 associated YAP (Fig. 6E, bottom panel).
Reduced S127-phosphorylated YAP and increased nuclear
presence of YAP would be expected to result in increased YAP-
driven transcription to drive proliferation of intestinal crypt cells in
the canonical Hippo pathway. Enhanced proliferation can be
observed in wild-type mice upon DSS treatment but not in DSS-
treated Rassf1a2/2 and Rassf1aIEC-KO mice (Fig. S5A). DSS-treated
Rassf1a2/2 and Rassf1aIEC-KO mice clearly revealed enhanced
nuclear levels of YAP but reduced crypt proliferation (as
determined by PCNA staining in Fig. S5A). However, increased
crypt apoptosis (as determined by elevated PARP cleavage and
TUNEL staining) can be observed in line with reduced crypt
proliferation (Fig. 6C – D). Furthermore, MST kinase activity was
dramatically reduced in DSS-treated of Rassf1a2/2 and Rassf1aIEC-
KO mice (Fig. S5B) in agreement with enhanced nuclear presence
of YAP.
Further detailed analysis revealed increased tyrosine phosphor-
ylation (pY) of YAP in DSS-treated Rassf1a2/2 mice in colon
lysates/nuclear fractions (Fig. 6F) and in colonic sections (Fig. 7A).
A clear difference in pY-YAP between DSS-treated wild type and
Rassf1a2/2 mice was observed as early as day 5 post DSS addition
that continued to increase towards day 9 (Fig. 7A, right panel).
Previous studies have suggested a functional role for pY-YAP/p73
complex to ultimately drive pro-apoptotic gene expression,
especially Bax [44,45]. In support of these arguments, we detected
enhanced nuclear presence of a pY-YAP/p73 complex (Fig. 6E,
bottom panel), increased Bax expression by immunohistochemis-
try and immunoblotting (Fig. 7B) in intestinal crypt cells from
DSS-treated Rassf1a2/2 and Rassf1aIEC-KO mice but not in samples
from wild-type or Rassf5a2/2 treated mice. This suggests that a
pY-YAP/p73 driven up-regulation of Bax may promote intestinal
cell death leading to increased gut permeability, lack of effective
epithelial repair and poor survival of DSS-treated Rassf1a2/2 and
Rassf1aIEC-KO mice.
Previous studies have suggested a functional role for c-Abl-
driven tyrosine 357 phosphorylation of YAP in response to DNA
damage [46,47]. This resulted in the formation of a pY-YAP/p73
complex to drive pro-apoptotic gene expression, especially Bax
[44,45]. We detected enhanced Y357 phosphorylation in Rassf1a
knockout mice using a Y357 YAP antibody (Fig. 6F and Fig. 7A).
In addition, we also observed increased DNA damage as early as
day 3 (Fig. 7C and Fig. S5C), oxidative damage by day 5 – 9
(Fig. 7D) as well as significant ROS production in colon samples
from in vivo DSS-treated Rassf1a knockout mice (Fig. S5D). DNA
and oxidative damage of colonic cells have been characterized as
significant factors in the pathogenesis of IBD [48,49]. Similar to
IBD patients, inflammation-induced injury in our Rassf1a knock-
out mice has associated DNA and oxidative damage. Since we can
observe DNA damage as early at day 3, we speculate that this may
be driving the tyrosine phosphorylation of YAP observed by day 3
– 5 (Fig. 7A). YAP tyrosine phosphorylation following DSS-
induced inflammation injury will in turn drive colonic cell death
(via p73 association and transcriptional activation of cell death
genes) and poor survival of DSS-treated Rassf1a knockout animals.
Imatinib can protect Rassf1a+/2 mice but not Rassf1a2/2
mice from DSS-induced inflammation injury
Next, we wanted to inhibit the protein tyrosine kinase (PTK) for
YAP in order to prevent a pY-YAP/p73 driven transcription of
pro-apoptotic genes (such as Bax) and possibly aid in promoting
the enhanced survival of DSS-treated Rassf1a knockout mice. As
mentioned earlier, YAP has been shown to be tyrosine phosphor-
ylated by c-Abl in response to DNA damage. Imatinib/gleevec
was developed to specifically inhibit c-Abl (IC50 of 25 nM) [50]
and has been successful utilized to treat leukemia patients.
However, it can also inhibit c-Kit and PDGF-R at 400 nM [50].
Imatinib treatment of our Rassf1a+/2 mice (IP injections of
60 mg/kg body weight of imatinib on day 3 and 6 of an acute 3%
DSS treatment) resulted in .80% survival (Fig. 8A), low disease
activity indices (Fig. S6A), low histopathological scoring of ,2
(Rassf1a+/2 mice normally have .6, Fig. 8B), reduced IL-6
(Fig. 8C), reduced cell death (Fig. 8D and Fig. S6B), reduced DNA
and oxidative damage (Fig. S6C – D, purity of nuclear extracts is
shown in S6E), regain normal crypt architecture (Fig, 8E and Fig.
S7A) and increased PCNA staining (increased proliferation, Fig.
S7A). Imatinib significantly reduced pY-YAP as determined by
immunohistochemical staining (Fig. 8E) and immunoblotting (Fig.
S7B). Furthermore, there was increased c-Abl kinase activity
towards FLAG-YAP in colon lysates from the Rassf1a+/2 mice that
was inhibited by imatinib (Fig. 8F). The increased kinase activity of
c-Abl was not inhibited by a direct modulation by RASSF1A as
exogenous addition of GST-RASSF1A did not interfere with the
kinase activity of c-Abl as determined by our in vitro method
(Fig. 8F, top panel, last two lanes on the right). Thus c-Abl activity
may be indirectly modulated by RASSF1A and increased c-Abl
activity is most likely a result of increased DNA damage during
intestinal inflammation. Taken together, our data suggested that
inhibition of the c-Abl class of PTKs was effective in reversing the
detrimental effects of a 3% DSS treatment in DSS-treated
Rassf1a+/2 mice.
In contrast to imatinib-treated Rassf1a+/2 mice, imatinib-
treated Rassf1a2/2 mice did have different survival outcomes.
We did notice that the clinical onset of disease was delayed 2 – 3
days when compared to DSS-treated Rassf1a+/2 or Rassf1a2/2
mice (Fig. 8A). Imatinib-treated Rassf1a2/2 mice had comparable
disease activity indices to imatinib-treated Rassf1a+/2 mice until
day 8, but by days 9 – 10, imatinib-treated Rassf1a2/2 mice wor-
sened with higher disease activity indices (Fig. S6A). Surprisingly,
DSS-treatment of Rassf1aIEC-KO vs Rassf1aIEC-WT mice on day 9. P value (Rassf1a IEC-WT vs Rassf1a- IEC-KO) = 0.003, n = 11. Bottom, Representation of how
colon length was measured. (E) Longitudinal cross-section of the descending colon stained with H&E from untreated and DSS-treated Rassf1aIEC-WT
and Rassf1aIEC-KO mice revealed severely disrupted colonic histology.
doi:10.1371/journal.pone.0075483.g004
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imatinib-treated Rassf1a2/2 mice revealed reduced pY-YAP 357
(Fig. 8E and Fig. S7C), reduced inflammation scores and cytokine
production (Fig. 8B and C) indicating that imatinib treatment was
interfering with a key mechanism promoting early intestinal
damage during the DSS treatment. However, the higher disease
activity indices on days 9 – 10 and poor survival of imatinib-
treated Rassf1a2/2 mice may be attributed to a robust degree of
cell death (Fig. 8D and Fig. S6B), DNA damage (Fig. S6C, bottom
panel) and c-Abl kinase activity following DSS-induced inflam-
mation. c-Abl kinase activity was, again, not affected by the
exogenous addition of GST-RASSF1A, Fig. 8F, bottom panel).
Equal amounts of FLAF-YAP were utilized as revealed by
Coomassie blue staining in Fig. S7D.
Further analysis of this discrepancy, revealed that the cleavage
of c-Abl was more apparent in DSS-treated Rassf1a2/2 mice
(Fig. 9A) and highly elevated in imatinib treated Rassf1a2/2 mice
(Fig. 9B), especially the presence of the predominant 25 kDa
cleaved (but active) fragment of c-Abl (Fig. 9A and B, marked with
‘‘*’’) [51,52]. Interestingly, DSS-treated wild type animals revealed
almost undetectable levels of p53 whereas DSS-treated Rassf1a+/2
or Rassf1a2/2 mice (Fig. 9C) revealed highly elevated or
accumulated levels of p53 (as early as day 3 for the DSS-treated
Rassf1a2/2 mice). The accumulation of p53 was more apparent by
day 9 and increased in imatinib-treated animals (Fig. 9C) whereby
p53 levels not only accumulated but p53 appears to be modified to
a slower migrating form around 75 kDa (Fig. 9 C, lanes 9 – 12).
Under DSS or imatinib treatment, p53 mRNA levels do not
appear to be significantly different, eliminating transcriptional
control (Fig. 9D). Evidence for p53 stabilization can be seen in Fig.
S7E and does reveal that imatinib can interfere with p53
Figure 5. RASSF1A intestinal cell-specific knockout (Rassf1aIEC-KO) animals have increased levels of inflammatory biomarkers. (A) DAI
for survival curve in Fig. 4B. P value = 0.0001 (Rassf1 IEC-WT and Rassf1aIEC-KO), n = 12. (B) Inflammation score of the indicated genotypes. P value
(Rassf1aIEC-WT and Rassf1aIEC-KO) = 0.02. (C and D) Blood serum levels of IL-6 and MCP-1 are shown (day 9). P values (Rassf1aIEC-WT and Rassf1aIEC-KO)
= 0.03 for IL-6 and 0.0003 for MCP-1 (n=6–10). (E) NFkB DNA binding activity in nuclear extracts as indicated (day 9). P values for quantitation results
= 0.010 (n = 7) for bone marrow cells and 0.0005 (n = 7) for crypt cells. (F) Tissue MPO activity as determined by ELISA (day 9), n=8 – 10. For (B) and (E)
all untreated results for Rassf1aIEC-KO were similar to Rassf1aIEC-WT (untreated).
doi:10.1371/journal.pone.0075483.g005
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Figure 6. Loss of RASSF1A results in altered intestinal homeostasis. (A) Gut permeability of the indicated animals was determined by FITC-
dextran fluorimetry on day 9 post-DSS addition. P values (all + DSS): wild-type vs Rassf1a2/2 = 0.007; wild-type vs Rassf5a2/2 = 0.4; Rassf1a2/2 vs
Rassf5a2/2 = 0.005, wild-type vs Rassf1aIEC-KO = 0.0001, n = 6 – 10 per group. (B) Right panel, bacterial translocation to blood and mesenteric lymph
nodes as indicated (liver and spleen also revealed some translocation). Left panel, histogram plot of the percentage of these four areas colonized
with bacteria. (C) Analysis for PARP cleavage was carried out as indicated on day 9 post-DSS treatment. ‘‘*’’ p value = 0.0028 and ‘‘**’’ = 0.0295, n = 5 –
7 for all genotypes and treatments. P value wild-type (+DSS) vs Rassf5a2/2 (+DSS) = 0.989. (D) TUNEL positive staining (bright dots) was carried out as
a late marker of cell death. These pictures are a representative of three independent histological sections from each genotype and treatment. The
mean number of cells/crypt shown was counted 6 times. P value wild-type (+DSS) vs Rassf1a2/2 or Rassf1aIEC-KO (+DSS) = 0.002 and 0.04 respectively.
(E) Colon lysates (top panel) or nuclear fraction of isolated crypt cells (bottom panel) from the indicated genotypes were used to detect total or
phosphoserine (S)127 YAP, total YAP and p73 in the nuclear fractions. For the top panel, the +DSS lanes are colon lysates from different DSS-treated
animals. All treatments and genotypes had similar levels of total p73 following total lysate analysis by immunoblotting (data not shown). (F)
Detection of total or pY-YAP as indicated. Purity of nuclear and cytoplasmic fractions are shown in Figure S6E. For (C – D) all untreated results for
Rassf1a2/2, Rassf5a2/2 and Rassf1aIEC-KO (untreated) were similar to wild type (untreated).
doi:10.1371/journal.pone.0075483.g006
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Figure 7. Rassf1a2/2 mice fail to recover following DSS treatment due to abnormal YAP signaling. (A) Phosphotyrosine (pY)-YAP
immunohistochemistry (IHC) with anti-Y357 YAP was carried out on colon sections as indicated. Left panel, IHC of colon sections using anti-Y357
YAP. Right panel, 1000 cells were scored for nuclear presence of YAP Y357. P value wild-type (+DSS) vs Rassf5a2/2 (+ DSS) = 0.396. (B) Top panel,
analysis of Bax expression by IHC was carried out as indicated on colonic tissue sections on day 9 post-DSS treatment. Bottom panel, expression of
Bax in colon lysates from day 9 DSS-treated animals as indicated (fold induction of the immunoblotting results are graphed in the right panel). For
graph, ‘‘*’’ p-value = 0.0093 and ‘‘**’’ = 0.041, n = 5 – 7 for all genotypes and treatments. P value wild-type (+DSS) vs Rassf5a2/2 (+DSS) = 0.546. (C)
Analysis for the DNA damage marker, phospho-c-H2AX, following in vivo DSS insult in colon lysates (experiment repeated twice with similar results).
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dependent ubiquitination and increased in the DSS and imatinib-
treated Rassf1a2/2 mice (Fig. S7D – E). Since c-Abl can be
caspase cleaved and its resultant active fragment can phosphor-
ylate the p53 inhibitor/E3 ligase, Mdm2 [53], we speculate that in
the absence of RASSF1A, DSS-induced inflammation injury can
result in accumulated p53 and significantly higher levels of cell
death and poor recovery following DSS-induced inflammation
injury.
Discussion
An underlying hallmark of many inflammatory diseases is the
enhanced activation of transcription factors, including NFkB and
elevated production of NFkB -regulated cytokines. These
responses are needed to promote innate immunity activation
and stimulate the repair process. No single animal model can
explain the pathogenesis of IBD suggesting that IBD has
multifactorial etiologies [54,55]. The present study argues that
RASSF1A is an important regulatory element to restrict NFkB
activity. Unrestricted NFkB activity can significantly contribute to
poor recovery following inflammation-induced injury and inhibit
the ability to promote efficient epithelial repair and survival
(Fig. 10).
We have demonstrated that DSS-treated Rassf1a2/2 and
Rassf1aIEC-KO mice have elevated NFkB activity. Mechanistically
RASSF1A appears to restrict complex formation of MyD88/
TRAF6/IRAK and thus interfere with NFkB activation (Fig. 10).
RASSF1A forms robust associations upon LPS or DSS stimulation
with the membrane proximal complexes MyD88/TLR4 and
TRAF6/IRAK2 (Fig. S8A – B) but not with TAK1, IKK or
TRADD/RIP1/TNF-R1 (data not shown) in order to restrict
NFkB activity. Since both LPS and DSS can stimulate TLR4, we
believe that RASSF1A functions through TLR4 to inhibit IKK
and the cytoplasmic/nuclear shuttling of NFkB. Indeed we have
observed a significant reduction in the production of the NFkB-
driven cytokine, IL-8, when RASSF1A was overexpressed in colon
cancer epithelial cells (Fig. S8C). Furthermore, enhanced ubiqui-
tination of TRAF6 can be observed in colon lysates from DSS-
treated Rassf1a2/2 but not wild-type mice (Fig. S8D) indicative of
elevated membrane proximal activation of the TLR pathway to
drive TRAF6 ubiquitination and subsequent NFkB activation
(Fig. 10).
We also have in vivo evidence to demonstrate that YAP becomes
tyrosine phosphorylated in response to DSS-induced inflammation
injury most likely by the c-Abl class of PTKs. YAP was originally
identified by its association with the YES Src tyrosine kinase [56]
and has been demonstrated to be a transcription factor whose
cytoplasmic/nuclear shuttling is controlled by post-translational
phosphorylation events [57] [58]. During DSS-induced inflam-
mation injury in both Rassf1a+/2 and Rassf1a2/2 mice, we
observed elevated level of nuclear tyrosine phosphorylated YAP,
enhanced YAP/p73 associations (Fig. 6E) and elevated levels of
Bax expression to promote apoptosis (Fig. 6 and 7). Recently, van
der Weyden et al. [59] demonstrated that the combined loss of
Rassf1a and Runx2 promoted the formation of oncogenic YAP1/
TEAD transcriptional complexes to promote tumorigenesis. We
observed reduced S127 phosphorylated YAP (possibly indicating
reduced YAP/TEAD transcriptional complexes) in DSS-treated
Rassf1a2/2 mice. We propose that our results demonstrate that the
early loss of Rassf1a can lead to enhanced inflammation, a key pre-
condition to cancer and inflammation driven activation of YAP/
p73 complexes to promote cell death. YAP1/TEAD complexes
may arise after prolonged chronic inflammation to promote
proliferation in support of the findings of van der Weyden et al.
[59]. It has been demonstrated that IL-6 can promote the
activation of DNA methyltransferase 1 (DNMT1) [24,60] and
DNMT1 can epigenetically silence RASSF1A [23,61] to provide a
mechanism whereby inflammation may drive epigenetic silencing
of RASSF1A and loss of the function of this tumor suppressor
protein.
The c-Abl tyrosine kinase can phosphorylate YAP upon DNA
damage, selectively promoting a YAP/p73 complex to drive the
expression of pro-apoptotic genes [47]. Since we cannot observe
inhibition of c-Abl kinase by exogenous addition of RASSF1A, we
speculate that NFkB may transcriptionally up-regulate a PTK or
that NFkB dependent-inflammation will promote DNA damage to
drive the tyrosine phosphorylation of YAP via c-Abl or c-Abl-like
kinases (Fig. 10). Either mode of regulation would result in an
abnormal tyrosine phosphorylation of YAP to yield increased
epithelial apoptosis and p53 accumulation to promote further
apoptosis. These events would result in poor survival following
intestinal inflammation induced injury. Inhibiting this abnormal
phosphorylation of YAP using the c-Abl class of PTK inhibitors
(imatinib) reversed the damaging effects of DSS induced intestinal
inflammation but only in a Rassf1a+/2 background. In a Rassf1a2/
2 background, imatinib partially reversed the effects of DSS-
induced inflammation but did not allow the animal to recover due
a robust accumulation of p53 towards day 9 that may have
resulted in more apoptosis and poor recovery. Interestingly, in day
9 imatinib-treated Rassf1a2/2 mice, p53 was accumulated and
modified (Fig. 9C, lane 9). We have not identified what this
modification is (most likely one of many p53 phosphorylated
residues) but we are currently exploring this and, if unique, may be
an interesting biomarker for disease prognosis.
It is known that caspase cleaved c-Abl can phosphorylate the
p53 E3 ligase, Mdm2, to inhibit Mdm2-dependent degradation of
p53 and allow it to accumulate [53]. Accumulated p53 can then
associate with the anti-apoptotic inhibitor, Bcl-2 to promote cell
death [62]. This may explain why imatinib-treated Rassf1a2/2
mice are not protected from DSS-induced inflammation and have
similar or enhanced cell death. Curiously, we cannot absolutely
eliminate tyrosine phosphorylation of YAP using imatinib (Fig.
S7B) nor most of the biomarkers of inflammation or cell death.
This would suggest that other PTKs may also influence tyrosine
phosphorylation of YAP upon inflammation induced injury in the
absence of RASSF1A. YES, the other known PTK for YAP, has
two NFkB binding sites within its promoter region (as documented
by http://www.genecards.org/cgi-bin/carddisp.pl?gene =YES1)
and could be up-regulated by NFkB activation due to the failure
of RASSF1A to restrict NFkB activation (Fig. 10). Preliminary
results do reveal increased c-YES expression upon DSS-induced
stimulation in Rassf1a+/2 and Rassf1a2/2 colon lysates (data not
shown). We are currently exploring how NFkB may regulate YES
expression, if YES kinase activity is elevated in DSS-treated
Rassf1a knockout mice and if the YES inhibitor, dasatinib, can
promote the survival of DSS-treated Rassf1a knockout mice.
Numbers represent fold induction relative to phospho-c-H2AX levels in untreated wild type animals. (D) Real time PCR analysis for an oxidative
damage marker hemexogenase-1 (HO-1) utilizing colonic mRNA (n = 4 for all and D designates the day that the tissues were harvested). P value of
wild type (+DSS) versus Rassf5a2/2 is 0.027 (Day 3), 0.006 (day 5) and 0.0008 (day 9) with n= 4 – 6 per day per sample. The Rassf1aIEC-KO result was
comparable to the result in the DSS treated Rassf1a2/2 mice (data not shown).
doi:10.1371/journal.pone.0075483.g007
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Figure 8. The PTK inhibitor, imatinib, inhibits the appearance of pY-YAP and promoted increased survival of Rassf1a+/2 but not
Rassf1a2/2 mice animals following inflammation-induced injury. (A) Rassf1a+/2 or Rassf1a2/2 mice were intraperitoneally injected with the
PTK inhibitor, imatinib at 50 mg/g body weight on days 3 and 6 following 3% DSS addition. P-value between survival of DSS-treated wild type and
Rassf1a+/2 was ,0.0001 (n = 17) and between DSS-treated Rassf1a+/2 (+ imatinib) versus DSS-treated Rassf1a+/2 was 0.0086 (n = 17). No significance
difference was observed between DSS-treated Rassf1a+/2 and DSS-treated Rassf1a2/2 (+ imatinib) mice (please see Fig. 1A for the survival curve of
DSS-treated Rassf1a2/2 mice). Following DSS/gleevec treatment, (B) histological analysis of colonic sections, (C) serum IL-6, (D) cell death via PARP
(late marker of apoptosis); (E) phospho-YAP by IHC, and (F) In vitro kinase activity was carried out for c-Abl using colon lystes from DSS-treated wild
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Our results demonstrate that the loss of Rassf1a resulted in the
loss of MST1 kinase activity (Fig. S5B) and the increased nuclear
presence of tyrosine phosphorylation of YAP (Fig. 6F and 7A). The
studies by van der Weyden et al. [59], Ren et al. [42], Cai et al.
[43], Zhou et al. [63] and Matallans et al. [64] explored MST/
RASSF1A dependent-regulation of YAP serine phosphorylation.
However, during intestinal inflammation in our system, YAP
transcriptional activities drive apoptosis in the absence of MST1/2
activity (see Fig. S5B). Recently, it was shown that YAP1 does not
require MST1/2 to drive the proliferation of keratinocytes [65] in
support of MST1/2 independent YAP functions. Furthermore,
although Matallans et al. [64] demonstrated that RASSF1A can
promote a YAP/p73 association they did not determine YAP
phosphorylation linked to S127 or Y357. We argue that intestinal
inflammation is driving a RASSF1A indirect affect on YAP
through elevated NFkB activity to transcriptionally up-regulate a
PTK to tyrosine phosphorylate YAP or, alternatively, in promot-
ing enhanced DNA damage to activate a YAP PTK. Either way, it
is an MST1/2 independent effect.
As mentioned earlier, DSS-treated YAP2/2 mice have de-
creased survival and proliferation and increased cell death upon
DSS treatment that is very similar to our inflammation phenotype
[43]. However, Cai et al. [43] did not explore tyrosine
phosphorylation of YAP but did show reduced YAP phospho-
S127 with increased time post-DSS addition [43]. We have
evidence that increased c-Abl cleavage (most likely by caspases)
and accumulated p53 may occur in parallel to p73/YAP driven
cell death following DSS-induced inflammation injury (based on
the results in Fig. 9C). This may explain why DSS-treated YAP2/2
mice have elevated apoptosis and poor survival in the absence of
YAP. It has been shown in chronic UC patients that p53 is up-
regulated in crypt cells and neutralizing antibodies to TNFa
reduce the levels of p53 and IBD-related symptoms of UC patients
[66] in support of the important role for p53 in intestinal
epithelial-dependent cell death. In addition to p53, PUMA (p53
up-regulated modulator of apoptosis) has been shown to be up-
regulated in intestinal cells following DSS treatment in mice and in
colonic biopsies from UC patients suggesting an important role for
other pro-apoptotic proteins in the pathogenesis of colitis [67].
Preliminary microarray analyses on colonic RNA isolated from
DSS-treated wild-type and Rassf1a2/2 mice revealed up-regula-
tion of several pro-apoptotic genes. These genes were increased 2
– 4 fold and include the death associated protein 3 (DAP3),
programmed cell death 10 (PDCD10), PRKC apoptosis WT1
regulator (PAWR) and death effector domain-containing (DEDD)
(data not shown). It will be interesting to explore if any of these are
transcriptionally regulated by YAP/p73 in response to intestinal
inflammation.
Efficient epithelial proliferation/repair is an integral part of
recovery following inflammation-induced injury [36]. Preliminary
data suggest that we can observe altered b-catenin/E-cadherin
adherens junctions on colon sections from DSS-treated Rassf1a
knockout mice during the recovery phase following DSS addition
(day 9, data not shown). Altered b-catenin/E-cadherin associations
together with elevation of tyrosine phosphorylated YAP, will result
in abnormal formation of epithelial junctions and the appearance
of a ‘‘leaky gut’’. Interestingly, YAP is overexpressed in CRC
patients and RASSF1A is epigenetically silenced in CRC patients
[12]. The loss of RASSF1A may, therefore, affect other aspects of
epithelial restitution with YAP activity an integral part of this
process. Failure to efficiently reseal and re-establish epithelial cell
homoestasis will lead to an unnecessary inflammatory response,
poor recovery and an early phase of colitis-associated carcinogen-
esis [68,69].
An important element for recovery from inflammation-induced
damage is efficient repair. During the pathogenesis of IBD, it has
been documented that DNA damage [70], oxidative damage
[71,72] and abnormal ROS levels [72] are elevated in a similar
manner to what we have observed for DSS-treated Rassf1a
knockout mice. Reactive oxygen species (ROS) are generated by
inflammatory cells, neutrophils and macrophages and surround
the inflamed mucosa [72]. High levels of ROS can lead to changes
in colonic membrane permeability, decreased mucosal barrier of
intestinal epithelial cells and to increased DNA and oxidative
damage. Both DNA and oxidative damage can lead to c-Abl
activation to drive the formation of tyrosine phosphorylated YAP
and a YAP/p73-dependent transcriptional program. Inhibitors of
ROS generation or DNA damage may be interesting angles to
pursue in the future.
In addition to c-Abl and YES as potential PTKs for YAP,
preliminary microarray analyses on colonic RNA isolated from
DSS-treated wild-type and Rassf1a2/2 mice revealed a 7.5 fold
increase in TNK2 (a tyrosine kinase, non receptor type 2 also
known as ACK1) and a 2.3 fold increase in c-Mer proto-oncogene
tyrosine kinase (MERTK) (data not shown). MERTK has several
potential NFkB binding sites (as documented by http://www.ge
necards.org/cgi-bin/carddisp.pl?gene =MERTK) and can modu-
late the autophosphorylation of TNK2. MERTK can also regulate
cytokine production and clearance of apoptotic cells. [73] Very
little is known about TNK2 other than its association with cdc42
in order to maintain it in a GTP bound form [74] and TNK2-
dependent tyrosine phosphorylation of the androgen and epider-
mal growth factor receptor [75]. These observations provide
interesting candidates to pursue that may function to drive the
tyrosine phosphorylation of YAP and a YAP/p73 transcriptional
program. Inhibiting the devastating effect of tyrosine phosphor-
ylated YAP/p73-driven activation of pro-apoptotic genes and
epithelial cell damage in the absence of RASSF1A may aid in
designing future treatment schemes for patients with chronic
inflammation. In fact, there has been one report to document the
beneficial effects of protein tyrosine kinase inhibitors in treating
IBD [26,76].
Our study provides a mechanistic understanding of DSS-
induced inflammation injury in the absence of RASSF1A.
Biomarker analyses for the Rassf1a+/2and Rassf1a2/2 mice
revealed similar outcomes suggesting similar mechanisms of
disease pathogenesis (except for responsiveness to imatinib). As
can be observed in Fig. 1A, we did notice a slight delay in the
appearance of clinical symptoms in the Rassf1a+/2 mice, especially
in the appearance of rectal bleeding. However, both Rassf1a+/
2and Rassf1a2/2 mice had similar survival rates at the end of the
experiment and the delay at the beginning of the experiment was
type and Rassf1a+/2 (top panel) and Rassf1a2/2 (bottom panel) mice with overexpressed FLAG-YAP as substrate. Expression levels of c-Abl were
similar in all the lanes (data not shown) and bacterially expressed GST or GST-1A (1A) was used to explore how RASSF1A may directly interfere with c-
Abl kinase activity. Expression of FLAG-YAP, GST and GST-1A are shown in Fig. S7D. For (B) p-value between wild type versus Rassf1a+/2 mice (+DSS)
was 0.004, wild type versus Rassf1a+/2 mice + DSS + gleevec) was 0.168 and wild type versus Rassf1a2/2 mice (+DSS + gleevec) was 0.452 (n = 4 – 8).
For (C), p-value between wild type versus Rassf1a+/2 mice (+DSS) was 0.004 and wild type versus Rassf1a+/2 mice (+ DSS + gleevec) was 0.347 and
wild type versus Rassf1a2/2 mice (+DSS + gleevec) was 0.262 (n = 4 – 8). For (E) P values of Rassf1a+/2 mice or Rassf1a2/2 mice (+DSS 2/+ gleevec)
was ,0.001 (n = 10).
doi:10.1371/journal.pone.0075483.g008
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Figure 9. The loss of RASSF1A results in cleavage of c-Abl and accumulation of p53. (A) Expression of c-Abl following DSS treatment as
indicated. Erk1/2 was used as loading control and D= days after DSS addition. (B) Imatinib treatment of Rassf1a2/2 mice (but not Rassf1a+/2 mice)
results in increased cleavage of c-Abl and sustained p25 cleaved form of c-Abl (indicated by *). (C) c-Abl cleavage can result in phosphorylation of
Mdm2 and stabilization of p53 to promote cell death. The loss of both alleles of Rassf1a results in increased expression of p53 and its modification. (D)
Reverse transcriptase analysis of p53 expression revealed no transcriptional changes in p53 expression following neither DSS treatment nor with
imatinib addition.
doi:10.1371/journal.pone.0075483.g009
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not statistically significant. We are currently exploring biomarker
analyses between day 0 and day 8 to explore molecular differences
between Rassf1a+/2and Rassf1a2/2 mice. Interestingly, it has
recently been demonstrated that p53 functions to recruit DAXX
and DNMT1 to CpG methylation sites on RASSF1A and
epigenetically silence RASSF1A [77]. p53 is accumulated in
DSS-treated animals, in IBD patients and can also silence
RASSF1A by direct promote regulation of epigenetic silencing
by DNA methylation of its promoter. Furthermore, RASSF1A
epigenetic silencing can be detected in ulcerative colitis patients
[22] and upon IL-6 production [23]. We, therefore, speculate that
chronic inflammation will result in the loss of epigenetic loss of
RASSF1A and RASSF1A may be in early change in the
pathogenesis of ulcerative colitis. The Rassf1a+/2, Rassf1a2/2
and Rassf1aIEC-KO mice may be useful models for understanding
IBD and other inflammatory disorders.
Supporting Information
Figure S1 Genotyping and characterization of DSS-
treated Rassf1a2/2 mice. (A) Crypt length of the indicated
genotypes and treatments. Data was obtained from several
histological sections similar to Fig. 1E. p value for the difference
in crypt depth between wild type (+DSS) vs Rassf1a2/2 mice
(+DSS) = 0.0004 (n= 14). (B) Histological representations of the
colon from DSS-treated Rassf1a2/2 mice at day 9. These sections
further confirm the results in Fig. 1E and revealed the presence of
lymphoid aggregates (dense circle of cells in top panel) in several
areas of DSS treated colonic sections from Rassf1a2/2 mice. This
would suggest active recruitment of immune cells to the inflamed
area. (C) Genotyping of Rassf1a2/2 and Rassf5a2/2 animals.
Immunoblot of a colon tissue preparation is shown in the bottom
panel for RASSF1A and the loss of RASSF5A in the Rassf5a2/2
mice has been published [3]. (D – E) Rassf1a2/2 animals show
increased levels of serum or tissue myeloperoxidase (MPO) (D) and
hyaluronic acid (HA, E). For Serum MPO, p-values wild type
(+DSS) vs Rassf1a2/2 mice (+DSS) ,0.0001; Rassf1a2/2 (+DSS)
vs Rassf5a2/2 mice (+DSS) 0.035. Tissue MPO, p-value [wild type
vs Rassf5a2/2 (+DSS)] = 0.2 and (C – F) wild type (+/+) vs
Rassf5a2/2 (treated) varied between 0.2 to 0.7 with n= 4–6. For
serum HA, p-values wild type (+DSS) vs Rassf1a2/2 mice (+DSS)
Figure 10. Model for RASSF1A regulation of NFkB and YAP. RASSF1A restricts NFkB activity by interfering with the ability of membrane
proximal TLR/MyD88/TRAF6/IRAK2/4 to promote downstream signaling to NFkB. This results in the interference of NFkB-dependent gene
transcription and the activation of inflammatory pathways. Through regulating NFkB activity (and early increases in DNA damage), RASSF1A indirectly
regulates the activity (and possibly the expression) of a PTK to tyrosine phosphorylation YAP (possibly through c-Abl or c-YES). Increased PTK activity
(in the absence of Rassf1a) would drive tyrosine phosphorylation of YAP and increased pY-YAP/p73 transcriptional up-regulation of pro-apoptotic
genes such as Bax. Increased levels of Bax (and other p73/pY YAP targets) results in apoptosis, intestinal inflammation, oxidative (and DNA damage)
and colonic injury. Sustained levels of apoptosis will result in the pro-apoptotic cleavage of c-Abl to stabilize p53. Accumulated p53 can further
promote cell death and further colonic injury and poor recovery following inflammation insults.
doi:10.1371/journal.pone.0075483.g010
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is 0.0043; Rassf1a2/2 (+DSS) vs Rassf5a2/2 mice (+DSS) 0.0099.
n = 10–15 for each biomarker.
(TIF)
Figure S2 Ex vivo analysis of BMDM and splenocytes
from the indicated genotypes. BMDM (A – D) and
splenoctyes (B, D – F) were cultured, stimulated with 0.2 mg/ml
LPS for 5 hours or 3% DSS for 16 – 20 hours as indicated.
Supernatants were harvested and secreted cytokines quantitated
by ELISA; n= 6. P-values between wild type and Rassf1a2/2 LPS-
stimulated cells are indicated and was found to be the same for
both BMDM and splenocytes in (B and D). P values between wild-
type and Rassf5a2/2 in S2E were 0.454. For (C), p-value = 0.7 by
One-way Anova analysis. n = 4–6 from 2 – 3 independent
experiments for all panels. P values for the differences between
Rassf5a2/2 versus wild-type for all panels was .0.1. For (A, C, E–
F) all untreated results for Rassf1a2/2 and Rassf5a2/2 were similar
to wild type (untreated). The NFkB inhibitor utilized was 10 mM
methoxyresveratrol.
(EPS)
Figure S3 Further characterization of DSS-treated in-
testinal cell-specific knockout (Rassf1aIEC-KO) animals.
(A) Crypt length of the indicated genotypes and treatments. Data
was obtained from several histological sections similar to Fig. 4E.
n = 15 and p-value Rassf1a IEC-WT vs Rassf1a IEC-KO (+DSS)
= 0.0001. (B) Tissue levels of hyaluronic acid were determined by
ELISA (day 9). P-value for the difference between Rassf1aIEC-WT
and Rassf1aIEC-KO (+DSS) was ,0.04, n = 4. (C – E) Ex vivo
analyses of BMDM and splenocytes from the indicated genotypes.
BMDM (C) or splenocytes (D) were cultured ex vivo and stimulated
with DSS for 16 – 20 hours or LPS for 5 hours. Supernatants were
harvested and the amount of secreted cytokines quantified by
ELISA; n= 4. p values Rassf1aIEC-WT vs Rassf1aIEC-KO DSS-
stimulated BMDM is = 0.8 for all cytokines in (C). p values
Rassf1aIEC-WT vs Rassf1aIEC-KO LPS-stimulated splenocytes = 0.002
(n = 8) for (D). (E) Immunoblot of colon and kidney tissue
preparations from Rassf1 IEC-WT and Rassf1aIEC-KO mice is shown.
For (B–E) all untreated results for Rassf1aIEC-KO and Rassf1aIEC-WT
were similar to wild type (untreated).
(EPS)
Figure S4 Normal kidney function in Rassf1aIEC-KO
animals following DSS treatment. Serum creatinine (A)
and systolic blood pressure (B) was measured as indicated (day 9
post-DSS treatment). P value was between 0.2 and 0.5 for the
differences between Rassf1aIEC-WT vs Rassf1 IEC-KO animals for
these measurements (n = 8–10 for the serum creatinine levels and
6 for the blood pressure measurements). (C) Kidney sections from
the indicated genotypes were analyzed after H&E staining and
were found to be unaltered with and without DSS treatment.
(TIF)
Figure S5 The loss of RASSF1A results in decreased
crypt cell proliferation and increased cell death follow-
ing DSS-induced inflammation injury. (A) Measurement of
PCNA positive proliferation in colonic sections. Biotinylated
PCNA staining was detected using diaminobenzidine (DAB)
streptavidin. HRP appears as a brown precipitated over the
H&E stained sections. ‘‘*’’ p value = 0.0001 and ‘‘**’’ = 0.0002, n
= 12–15 for all genotypes and treatments. P value wild type
(+DSS) vs Rassf5a2/2 (+DSS) = 0.719. Percent PCNA staining
was calculated by counting 4 groups of ,100 cells in three
independent histological sections from each genotype and
treatment. (B) MST1 in vitro kinase assay was carried out on colon
lysates from the indicated genotypes using Histone H2B. MST1
expression is shown for the 2/+ DSS-treated Rassf1a2/2 mice.
Similar results were obtained for the other genotypes and
experiment was carried out twice with similar results. (C) Time
course analysis of DNA damage utilizing expression of phospho-c-
H2AX as observed in Fig. 7C. (D) Fluorometric analysis of
production of reactive oxygen species (ROS) using intracellular
oxidation of 29,79-dichlorofluorescin diacetate (DCF-DA) by
freshly isolated colon crypt cells from the indicated genotypes. P
values wild-type (+/+, +DSS) vs Rassf1a2/2 or Rassf1a+/2 mice
(+DSS) ,0.0001; wild type (+DSS) vs Rassf1aIEC-KO mice
= 0.0006; wild type (+DSS) vs Rassf5a2/2 mice (+DSS) 0.083
(n= 8 for all genotypes). For (A and C) all untreated results for
Rassf1a2/2, Rassf5a2/2, Rassf1aIEC-KO were similar to wild type
(untreated).
(TIF)
Figure S6 The PTK inhibitor, imatinib reverses the
damaging effects of DSS treatment in the Rassf1a+/2 but
not Rassf1a2/2 knockout mice. Imatinib was administered
intraperitoneally at 50 mg/g body weight on day 3 and 6 and (A)
Disease activity index, (B) cell death using Bax immunoblotting (as
an early marker of apoptosis) (in colon lysates), (C) the DNA
damage marker phospho-c-H2AX (in colon lysates) and (D) the
oxidative damage marker, HO-1was carried out as indicated
(source of sample was colonic mRNA). (E) Purity of our nuclear
and cytoplasmic fractions was tested as indicated.
(EPS)
Figure S7 Further analysis of biomarkers of intestinal
inflammation were analyzed. (A) PCNA staining with
quantitation on the right panel, (B) Detection of pY-YAP was
carried out as indicated, (C) pY-YAP immunohistochemistry
carried out, (D) Expression of FLAG-YAP (top panel), GST and
GST-1A (bottom panel) used in in vitro kinase assay in Fig. 8F.(E)
Ubiqutination of p53 was carried out as indicated in colon lysate
samples. All baseline (untreated) results not shown were signifi-
cantly not different from wild type (untreated).
(TIF)
Figure S8 RASSF1A restricts NFkB signaling by associ-
ation with membrane proximal complexes. (A – B) HT-29
(a colon epithelial cancer) cells were transiently transfected with
vector (-) or HA-tagged RASSF1A (HA-1A). Fourty-eight hours
after transfection, cells were grown in serum free media for two
hours followed by (A) 1 mg/ml LPS addition or (B) 3% DSS in the
media, lysed and immunoprecipitated with the indicated antibod-
ies. Associated proteins were separated on SDS-PAGE and
immunoblotted. (C) HT-29 (colon epithelial cancer) cells were
transiently transfected with vector (-) or HA-tagged RASSF1A
(HA-1A). Fourty-eight hours after transfection, cells were grown in
serum free media for two hours followed by the addition of 1 mg/
ml LPS or 3% DSS for 5 hours. One mL of the supernatant was
harvested and IL-8 levels determined. Inset, expression of HA-1A
in HT-29 cells. Similar results were obtained for HCT-116 cells
(data not shown). (D) Colon extracts were prepared from the
indicated genotypes 2/+DSS treated, immunoprecipitated with
anti-TRAF6 and immunoblotted as indicated. Lysates from two
animals/treatement/genotype were analyzed as indicated.
(EPS)
Methods S1 Supplementary Methods Text S1.
(DOCX)
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